Novo Nordisk explores Wegovy combinations as shares fall
The company is pursuing combination regimens and broader semaglutide indications while investors mark the stock down.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 8 03:00 ETSource: Yahoo Finance
The wire
- 01Novo Nordisk is looking at Wegovy combination approaches and wider benefits for semaglutide beyond weight loss, with shares declining on the day.
- 02Label expansion and combination work shape what prescribers can offer semaglutide patients over the next several years.
- 03Specific combination partners, trial designs and timelines were not detailed; treat the plans as company statements until data or filings appear.
From the source
Read at finance.yahoo.comNovo Nordisk Explores Wegovy Combination And Wider Semaglutide Benefits As Shares Fall